Evogene Analyst Ratings
Evogene Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/02/2023 | 213.56% | Alliance Global Partners | → $1.85 | Initiates Coverage On | → Buy |
| 08/18/2023 | 408.47% | Lake Street | $2 → $3 | Maintains | Buy |
| 07/21/2023 | 916.95% | Roth MKM | $1 → $6 | Maintains | Buy |
| 05/02/2023 | 238.98% | Lake Street | → $2 | Initiates Coverage On | → Buy |
| 09/12/2022 | 1255.93% | Aegis Capital | $10 → $8 | Maintains | Buy |
| 09/02/2022 | 408.47% | Roth MKM | $6 → $3 | Maintains | Buy |
| 10/08/2021 | 1086.44% | Roth Capital | → $7 | Initiates Coverage On | → Buy |
| 07/29/2021 | 1594.92% | Aegis Capital | → $10 | Initiates Coverage On | → Buy |
| 12/01/2020 | 1425.42% | Cantor Fitzgerald | → $9 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 10/02/2023 | 213.56% | 聯盟全球合作夥伴 | →$1.85 | 開始承保 | →購買 |
| 2023年08月18日 | 408.47% | 萊克街 | $2→$3 | 維護 | 買 |
| 07/21/2023 | 916.95% | 羅斯MKM | $1→$6 | 維護 | 買 |
| 05/02/2023 | 238.98% | 萊克街 | →$2 | 開始承保 | →購買 |
| 09/12/2022 | 1255.93% | 宙斯盾資本 | $10→$8 | 維護 | 買 |
| 09/02/2022 | 408.47% | 羅斯MKM | $6→$3 | 維護 | 買 |
| 10/08/2021 | 1086.44% | 羅斯資本 | →$7 | 開始承保 | →購買 |
| 07/29/2021 | 1594.92% | 宙斯盾資本 | →$10 | 開始承保 | →購買 |
| 12/01/2020 | 1425.42% | 康託·菲茨傑拉德 | →$9 | 開始承保 | →超重 |
What is the target price for Evogene (EVGN)?
Evogene(EVGN)的目標價是多少？
The latest price target for Evogene (NASDAQ: EVGN) was reported by Alliance Global Partners on October 2, 2023. The analyst firm set a price target for $1.85 expecting EVGN to rise to within 12 months (a possible 213.56% upside). 4 analyst firms have reported ratings in the last year.
聯盟全球合作夥伴於2023年10月2日報道了Evogene(納斯達克：EVGN)的最新目標價。這家分析公司將目標價定為1.85美元，預計EVGN將在12個月內升至(可能上漲213.56%)。去年有4家分析公司公佈了評級。
What is the most recent analyst rating for Evogene (EVGN)?
Evogene(EVGN)的最新分析師評級是多少？
The latest analyst rating for Evogene (NASDAQ: EVGN) was provided by Alliance Global Partners, and Evogene initiated their buy rating.
聯盟全球合作夥伴提供了對Evogene(納斯達克代碼：EVGN)的最新分析師評級，Evogene啟動了他們的買入評級。
When is the next analyst rating going to be posted or updated for Evogene (EVGN)?
Evogene(EVGN)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Evogene, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Evogene was filed on October 2, 2023 so you should expect the next rating to be made available sometime around October 2, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與Evogene的高管和客戶交談，以及收聽收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Evogene的最後一次評級是在2023年10月2日提交的，所以你應該預計下一次評級將在2024年10月2日左右的某個時候提供。
Is the Analyst Rating Evogene (EVGN) correct?
分析師評級Evogene(EVGN)正確嗎？
While ratings are subjective and will change, the latest Evogene (EVGN) rating was a initiated with a price target of $0.00 to $1.85. The current price Evogene (EVGN) is trading at is $0.59, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Evogene(EVGN)評級是以0.00美元至1.85美元的目標價啟動的。目前Evogene(EVGN)的交易價格為0.59美元，在分析師的預測範圍內。